34.12
-0.06 (-0.18%)
| Penutupan Terdahulu | 34.18 |
| Buka | 33.90 |
| Jumlah Dagangan | 57,183 |
| Purata Dagangan (3B) | 112,353 |
| Modal Pasaran | 319,645,024 |
| Harga / Jualan (P/S) | 32.17 |
| Harga / Buku (P/B) | 1.76 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Mar 2025 - 28 Mar 2025 |
| Margin Operasi (TTM) | -981.18% |
| EPS Cair (TTM) | -9.42 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 32.52% |
| Nisbah Semasa (MRQ) | 9.41 |
| Aliran Tunai Operasi (OCF TTM) | -62.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -61.34 M |
| Pulangan Atas Aset (ROA TTM) | -29.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -60.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Korro Bio, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.50 |
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 6.18% |
| % Dimiliki oleh Institusi | 104.23% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| 72 Investment Holdings, Llc | 30 Sep 2024 | 276,831 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 147.00 (Raymond James, 330.83%) | Beli |
| Median | 90.00 (163.78%) | |
| Rendah | 25.00 (Chardan Capital, -26.73%) | Beli |
| Purata | 87.33 (155.95%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 18.93 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 13 Aug 2025 | 25.00 (-26.73%) | Beli | 18.93 |
| HC Wainwright & Co. | 13 Aug 2025 | 90.00 (163.77%) | Beli | 18.93 |
| 24 Jul 2025 | 100.00 (193.08%) | Beli | 15.90 | |
| Raymond James | 13 Aug 2025 | 147.00 (330.83%) | Beli | 18.93 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Aug 2025 | Pengumuman | Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates |
| 21 Jul 2025 | Pengumuman | Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |